SweetValueLab
Write for us

Edwards Lifesciences Corporation — Intrinsic Value & Fair Price

EW
NYSEHealthcareMedical - DevicesCIK 0001099800edwards.comAbout EW
Last close · Oct 16, 202686.60−1.50 (−1.70%)
Market cap$49.9B
Model value · DCF · Perpetuity growth · 5y
44.31
Edwards Lifesciences closed at $86.60 — overvalued by 95% vs model.
31.20the model's range85.45

DCF · Perpetuity growth · 5y leads for mature & stable — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.

Other models
26.26 – 111.69
Wall St. target
101.00 14% below
Above model, 1y
17 of 20 days

Price and model value

Embed this card

EW's close against its model value, as a 420×168 card for your own page. It updates nightly with this site and links back here.

Free to embed; keep the attribution link.
Loading chart…
What the marks mean
Daily close

Research on EW

No posts on EW yet.
Studied EW from its filings? Guest posts are reviewed before they go live.Write about EW →

How it is valued

Valued asMature & Stable
Low/slowing growth (~1% recent)Moderate margins (18% net margin)Highly cyclical earnings
What growth the price implies: the reverse DCF

Key figures

FY2025
P/E
47.3×
EV / EBITDA
33.3×
FCF yield
2.6%
Dividend yield, TTM
0.00%
Beta
0.86
Cost of capital (WACC)
8.80%
Full financials

Analyst actions

third-party, quoted
07-28UBS · target110.00
07-24Leerink Partners · “Outperform” from “Market Perform”upgrade
07-24Leerink Partners · target101.00
07-24Piper Sandler · target101.00
Ratings, targets and estimates

Comparable companies

by business, not by industry label
3 more companies list EW as a comparable

The weekly

One email a week across every stock we cover: 13F filings, insider trades, earnings and new research. It covers the whole market, not just EW. No account.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

CEO
Bernard J. Zovighian
Headquarters
Irvine, CA
Employees
16,000
IPO
2000-03-27
Full company profile

Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; the formulas are in how we value a stock.